MK 0893: Dual Glucagon Receptor Antagonist and IGF-1R Inhibitor for Advanced Research

Executive Summary: MK 0893 is a potent, selective, and orally bioavailable small molecule antagonist that targets both the glucagon receptor (GCGR) and insulin-like growth factor 1 receptor (IGF-1R), with IC₅₀ values of 6.6 nM and 6 nM, respectively (Jazayeri et al. 2016). It acts as a competitive, reversible inhibitor of the GCGR and reduces cAMP production in human GCGR-expressing cells at physiological temperatures (37°C) (MK-0822.com). MK 0893 demonstrates in vivo efficacy by significantly blunting glucagon-induced glucose excursions in hGCGR mouse models (LProlineCatalog). The compound binds to a novel extra-helical allosteric site on the GCGR, as revealed by high-resolution X-ray crystallography (Jazayeri et al. 2016). APExBIO supplies MK 0893 (A3608) in high-purity formats for research use only (APExBIO).

Biological Rationale

The glucagon receptor (GCGR) is a class B G-protein-coupled receptor (GPCR) crucial for glucose homeostasis. It is expressed in liver, kidney, intestinal smooth muscle, brain, adipose tissue, heart, and pancreas (Jazayeri et al. 2016). Glucagon, a 29-amino-acid peptide, binds GCGR to stimulate hepatic glucose production, opposing insulin actions. Dysregulation of GCGR signaling contributes to hyperglycemia in type 2 diabetes. IGF-1R, a receptor tyrosine kinase, mediates growth and survival signals, and its aberrant activation is implicated in cancer and metabolic disorders (AlpidemBio). Dual targeting of GCGR and IGF-1R, as enabled by MK 0893, allows for the simultaneous dissection of metabolic and oncogenic signaling pathways.

Mechanism of Action of MK 0893 (Glucagon receptor/IGF-1R antagonist)

MK 0893 competitively and reversibly antagonizes the glucagon receptor by binding to an extra-helical allosteric site located between transmembrane helices 6 and 7, as determined by X-ray crystallography at 2.5 Å resolution (Jazayeri et al. 2016). This binding restricts the outward movement of TM6 required for G-protein coupling and receptor activation. Schild analysis confirms that inhibition is competitive and reversible in cellular models expressing human GCGR. MK 0893 also inhibits IGF-1R signaling, though the precise binding mode at IGF-1R has not been structurally resolved. Both GCGR and IGF-1R antagonism occur at nanomolar concentrations (IC₅₀: GCGR = 6.6 nM, IGF-1R = 6 nM) (APExBIO). Inhibition of GCGR blocks glucagon-induced cAMP production, while IGF-1R antagonism disrupts downstream proliferative and metabolic signaling pathways.

Evidence & Benchmarks

• MK 0893 binds the human GCGR at an extra-helical allosteric site, as confirmed by X-ray crystallography at 2.5 Å (Jazayeri et al. 2016, DOI).
• The compound exhibits an IC₅₀ of 6.6 nM for GCGR inhibition and 6 nM for IGF-1R, as measured in cell-based assays (APExBIO).
• MK 0893 reduces cAMP production in human GCGR-expressing cells at 37°C, as shown by Schild analysis (MK-0822.com).
• In hGCGR mouse models, MK 0893 blunts glucagon-induced glucose excursions, demonstrating in vivo efficacy (LProlineCatalog).
• In IGF-driven mouse xenograft models, MK 0893 shows robust efficacy against tumor growth (AktPathway).
• MK 0893 is orally bioavailable and stable as a solid at -20°C; soluble at ≥24.05 mg/mL in DMSO and ≥4.8 mg/mL in ethanol with gentle warming and ultrasonication (APExBIO).
• Structural mutagenesis confirms the involvement of key GCGR residues in antagonist binding (Jazayeri et al. 2016, DOI).

Applications, Limits & Misconceptions

MK 0893 is primarily a research tool for elucidating the glucagon receptor and IGF-1R signaling pathways. It is validated for use in in vitro cell assays and in vivo mouse models of type 2 diabetes and IGF-driven cancers (FexinidazoleSupply). Researchers may use MK 0893 to dissect cAMP-mediated metabolic responses, glucose homeostasis, and tumorigenic IGF-1R signaling. APExBIO supplies the compound for non-clinical, scientific research only; it is not approved for therapeutic or diagnostic use in humans or animals. MK 0893's specificity for human GCGR and IGF-1R should be verified in cross-species studies.

Common Pitfalls or Misconceptions

• Not a clinical drug: MK 0893 is not approved for clinical therapy or diagnostics; research use only (APExBIO).
• Species selectivity: Efficacy and binding may differ in non-human orthologs; confirm target conservation prior to use (Jazayeri et al. 2016).
• Solubility limits: MK 0893 is insoluble in water; use DMSO or ethanol with proper dissolution techniques (APExBIO).
• Stability: Avoid long-term storage of solutions; store solid at -20°C and prepare fresh aliquots (APExBIO).
• IGF-1R binding mode unresolved: Binding mechanism for IGF-1R is not structurally defined; interpret IGF-1R antagonism data accordingly.

Workflow Integration & Parameters

MK 0893 (A3608) is supplied by APExBIO as a solid or in DMSO solution, with recommended storage at -20°C (APExBIO). Prepare working stocks in DMSO (≥24.05 mg/mL) or ethanol (≥4.8 mg/mL) using gentle warming and ultrasonication. For cell-based assays, dilute to desired concentration in culture medium with a final DMSO content ≤0.1%. For in vivo studies, vehicle and dosing regimens should be optimized based on published protocols (LProlineCatalog). Avoid repeated freeze-thaw cycles. MK 0893 is compatible with cAMP quantification assays, glucose tolerance tests, and tumor xenograft models. For dual-pathway interrogation or combination studies, titrate concentrations to account for both GCGR and IGF-1R inhibition. This article extends the guidance found in AlpidemBio by detailing the allosteric binding mechanism and solubility parameters.

Conclusion & Outlook

MK 0893 exemplifies the next generation of dual-pathway modulators for metabolic and oncogenic research. Its unique allosteric binding to GCGR, coupled with robust IGF-1R inhibition, enables precise dissection of signaling events underlying type 2 diabetes and IGF-driven malignancies (Jazayeri et al. 2016). As a research reagent from APExBIO, MK 0893 (A3608) supports advanced experimental workflows but is not a substitute for clinical-grade compounds. Further studies may resolve the IGF-1R binding interface and expand translational applications. For additional background and data, see the product page for MK 0893 (Glucagon receptor/IGF-1R antagonist).